CagriSema is a subcutaneous injectable combination of cagrilintide and semaglutide that is currently in phase 3 trials.
Vidhi Patel, PharmD Candidate
Advertisement
Articles by Vidhi Patel, PharmD Candidate
Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.
Thiazolidinediones may change metabolic patterns and contribute to weight gain.
Advertisement
Latest Updated Articles
An Overlook of Cagrilintinide and Semaglutide as it Progresses Through Phase 3 TrialsPublished: November 11th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
Pharmacy Policy Updates for October 2025
3
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
4
UConn’s Medical Writing Certificate Program: It’s Just "Write"
5
